Melphalan Tillomed (Melphalan)

Melphalan belongs to the nitrogen‑mustard class of alkylating agents. It forms covalent bonds with the N7 position of guanine in DNA, creating cross‑links that block DNA replication and transcription. This damage triggers programmed cell death, preferentially affecting rapidly dividing cancer cells.

The specific dose of melphalan is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area, renal function and prior therapies. Dosing regimens vary widely, so the prescriber sets the exact amount and schedule for each individual.

Melphalan is classified as contraindicated in pregnancy and breastfeeding because it can cross the placenta and is excreted in breast milk, posing a risk of fetal or infant toxicity. Use is only considered when the potential benefit to the mother outweighs the potential risk to the child, and only under specialist supervision.

To request Melphalan Tillomed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Melphalan shares the DNA‑alkylating mechanism of other nitrogen‑mustard agents such as cyclophosphamide, but it is more lipophilic, allowing better penetration into certain tumour types like multiple myeloma. Its toxicity profile is similar, with notable myelosuppression, but dosing schedules and approved indications differ across agents.

Melphalan Tillomed should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperatures. Follow standard aseptic techniques when preparing the intravenous solution, and dispose of any unused material according to local hazardous‑waste regulations.

Melphalan Tillomed is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the treating physician, often over 30 minutes to several hours, depending on the prescribed dose and the patient’s tolerance.

The most serious risks include severe myelosuppression leading to life‑threatening infections, secondary malignancies, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Patients should be monitored closely for signs of infection, respiratory distress, and changes in kidney function throughout treatment.

Melphalan is contraindicated in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in those with active uncontrolled infections, and in pregnant or breastfeeding women unless the therapeutic benefit justifies the risk. Caution is also advised for patients with severe hepatic or renal dysfunction.